Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER-2 Positive Metastatic Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT01674062
What this trial is testing

Perjeta (Pertuzumab) in Combination With Herceptin (Trastuzumab) in Participants With Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 95
Testing effectiveness (Phase 2)Looking for participantsNCT06374459
What this trial is testing

Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis

Who this might be right for
Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer
Washington University School of Medicine 152
Testing effectiveness (Phase 2)WithdrawnNCT01137994
What this trial is testing

A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer

Who this might be right for
Neoplasms, Breast
GlaxoSmithKline
Testing effectiveness (Phase 2)Ended earlyNCT02154529
What this trial is testing

Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer

Who this might be right for
HER-2 Positive Breast CancerMetastatic Malignant Neoplasm to Brain
Kadmon Corporation, LLC 17
Not applicableStudy completedNCT04498481
What this trial is testing

TREATMENT AND MONITORING PATTERNS AND CLINICAL OUTCOMES IN PATIENTS RECEIVING PALBOCICLIB COMBINATION TREATMENT (WITH AI OR FULVESTRANT) FOR HR+/HER2- A/MBC IN A COMMUNITY ONCOLOGY SETTING.

Who this might be right for
Breast Cancer
Pfizer 1
Large-scale testing (Phase 3)UnknownNCT02344472
What this trial is testing

Detect V / CHEVENDO (Chemo vs. Endo)

Who this might be right for
Metastatic Breast Cancer
Prof. Wolfgang Janni 271
Testing effectiveness (Phase 2)Active Not RecruitingNCT04225117
What this trial is testing

Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

Who this might be right for
Locally Advanced or Metastatic Malignant Solid Tumors
Astellas Pharma Global Development, Inc. 329
Large-scale testing (Phase 3)Ended earlyNCT03199885
What this trial is testing

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

Who this might be right for
Metastatic Breast AdenocarcinomaMetastatic HER2-Positive Breast CarcinomaRecurrent Breast Adenocarcinoma+5 more
National Cancer Institute (NCI) 190
Large-scale testing (Phase 3)Looking for participantsNCT07294508
What this trial is testing

Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer

Who this might be right for
HER2 + Breast Cancer
Shanghai Henlius Biotech 706
Testing effectiveness (Phase 2)Looking for participantsNCT07299825
What this trial is testing

A166 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer

Who this might be right for
Her 2 Positive Breast Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. 40
Early research (Phase 1)Study completedNCT00140738
What this trial is testing

Safety and Immunogenicity Study of the New dHER2 Vaccine to Treat HER2-positive Metastatic Breast Cancer

Who this might be right for
Neoplasms, Breast
GlaxoSmithKline 3
Testing effectiveness (Phase 2)Ended earlyNCT00138125
What this trial is testing

Fulvestrant and/or Trastuzumab as First-Line Therapy in Treating Postmenopausal Women With Stage IV Breast Cancer

Who this might be right for
Breast Cancer
Translational Oncology Research International 2
Not applicableStudy completedNCT06305702
What this trial is testing

Real-world Study of Inetetamab in HER2-positive Metastatic Breast Cancer

Who this might be right for
HER2-positive Metastatic Breast Cancer
Liaoning Cancer Hospital & Institute 500
Testing effectiveness (Phase 2)UnknownNCT05823623
What this trial is testing

Inetetamab Combined With Pyrotinib Plus Oral Vinorelbine for the Treatment of HER2-positive Metastatic Breast Cancer

Who this might be right for
Breast Cancer
The First Affiliated Hospital with Nanjing Medical University 30
Not applicableUnknownNCT02642458
What this trial is testing

Pertuzumab in First Line Treatment of HER2-positive Metastatic Breast Cancer Patients

Who this might be right for
Metastatic Breast Cancer
University Hospital Tuebingen 300
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07630103
What this trial is testing

Efficacy and Safety of Trastuzumab Rezetecan or Trastuzumab Deruxtecan in Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 100
Testing effectiveness (Phase 2)Ended earlyNCT00817362
What this trial is testing

Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast Cancer

Who this might be right for
Breast CancerHER2 Positive Breast CancerMetastatic Breast Cancer+1 more
Infinity Pharmaceuticals, Inc. 29
Early research (Phase 1)Study completedNCT01471847
What this trial is testing

A Phase Ib/II Study of BEZ235 and Trastuzumab in Patients With HER2-positive Breast Cancer Who Failed Prior to Trastuzumab

Who this might be right for
Locally Advance Breast Cancer (LABC)Metastatic Breast Cancer (MBC)
Novartis Pharmaceuticals 5
Testing effectiveness (Phase 2)Looking for participantsNCT05816655
What this trial is testing

Comparison of Clinical Efficacy Between Letrozole + Ribociclib and Fulvestrant + Letrozole + Ribociclib in Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Korea University Guro Hospital 202
Large-scale testing (Phase 3)Study completedNCT05629949
What this trial is testing

A Multicenter, Double-blind, Randomized, Parallel-group, Phase III Study of the Efficacy and Safety of QL1701 Plus Docetaxel Versus Herceptin® Plus Docetaxel as First Line Therapy in Patients With HER2-positive Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Qilu Pharmaceutical Co., Ltd. 474
Next Page